Because BPC-157 is actively listed in Category 2, the FDA has determined that it poses significant safety risks, specifically regarding immunogenicity, structural impurities, and a distinct lack of human safety data
Key ways GLP-1s support insulin function: Increase insulin release when glucose is high, not when its normal Improve insulin timing so blood sugar stays more stable Decrease liver glucose output, especially between meals Slow gastric emptying, leading to more gradual glucose absorption Improve insulin sensitivity, so cells respond better to insulin Why this matters for weight loss and metabolic health: Lower insulin levels make it easier for the body to access stored fat Fewer blood sugar swings means less hunger and fewer cravings Reduced insulin resistance supports long-term metabolic improvement, not just short-term weight loss More stable glucose improves energy, focus, and mood Your medication is helping your insulin work smarter, not harder
When people dont feel hungry all the time, it becomes much easier to make good choices about what to eat or how much to eat. Are all GLP-1 drugs the same
These variations are shown graphically in Figure 1
